Key result
Advanced therapies for high- and intermediate-risk pulmonary embolism, including systemic thrombolysis and catheter-directed interventions, are reviewed alongside ongoing clinical trials.
Why the study?
Current PE risk stratification tools poorly predict short-term deterioration or long-term consequences, and randomized trial data supporting catheter-directed interventions are limited.
Population
Patients with high- and intermediate-risk pulmonary embolism
Design
Review
Authors
Loading...
Better risk tools needed to guide thrombolysis decisions in PE; leaves open optimal selection for short- and long-term outcomes.
This review summarizes current evidence and ongoing trials for advanced therapies in intermediate- and high-risk pulmonary embolism, highlighting the shift towards catheter-directed interventions to mitigate bleeding risks.
Mojaddedi et al. (2024) conducted a review in Acute pulmonary embolism (PE). Advanced therapies (systemic thrombolysis, catheter-directed interventions) was evaluated. Advanced therapies for high- and intermediate-risk pulmonary embolism, including systemic thrombolysis and catheter-directed interventions, are reviewed alongside ongoing clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: